JP2007505163A - Ｓａｒｓ感染の画像解析可能な動物モデル - Google Patents
Ｓａｒｓ感染の画像解析可能な動物モデル Download PDFInfo
- Publication number
- JP2007505163A JP2007505163A JP2006533504A JP2006533504A JP2007505163A JP 2007505163 A JP2007505163 A JP 2007505163A JP 2006533504 A JP2006533504 A JP 2006533504A JP 2006533504 A JP2006533504 A JP 2006533504A JP 2007505163 A JP2007505163 A JP 2007505163A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- group
- coronavirus
- animal model
- fluorescence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010171 animal model Methods 0.000 title claims abstract description 12
- 208000015181 infectious disease Diseases 0.000 title claims description 14
- 238000010191 image analysis Methods 0.000 title claims 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 title description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 241000711573 Coronaviridae Species 0.000 claims description 34
- 239000005090 green fluorescent protein Substances 0.000 claims description 33
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 32
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 32
- 102000034287 fluorescent proteins Human genes 0.000 claims description 26
- 108091006047 fluorescent proteins Proteins 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 11
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 101710172711 Structural protein Proteins 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 5
- 108010028403 hemagglutinin esterase Proteins 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 229960004854 viral vaccine Drugs 0.000 claims description 4
- 101710147732 Small envelope protein Proteins 0.000 claims description 3
- 101710114810 Glycoprotein Proteins 0.000 claims description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 2
- 101710167605 Spike glycoprotein Proteins 0.000 claims description 2
- 108091005981 phosphorylated proteins Proteins 0.000 claims description 2
- 108700010904 coronavirus proteins Proteins 0.000 claims 8
- 229940000406 drug candidate Drugs 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 108060003393 Granulin Proteins 0.000 claims 1
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 26
- 108010054624 red fluorescent protein Proteins 0.000 description 24
- 241000711466 Murine hepatitis virus Species 0.000 description 22
- 241000700605 Viruses Species 0.000 description 17
- 238000003384 imaging method Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 244000052769 pathogen Species 0.000 description 11
- 239000003086 colorant Substances 0.000 description 9
- 230000005284 excitation Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 230000029812 viral genome replication Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 238000000799 fluorescence microscopy Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108091027544 Subgenomic mRNA Proteins 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101001075376 Bos taurus Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 1
- 101100151951 Homo sapiens SARS1 gene Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 102100029137 L-xylulose reductase Human genes 0.000 description 1
- 108010080643 L-xylulose reductase Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 241000242743 Renilla reniformis Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108010046983 Ribonuclease T1 Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067674 Viral Nonstructural Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000011846 endoscopic investigation Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000006394 virus-host interaction Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47369103P | 2003-05-27 | 2003-05-27 | |
| PCT/US2004/016976 WO2004106497A2 (en) | 2003-05-27 | 2004-05-27 | Imageable animal model of sars infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505163A true JP2007505163A (ja) | 2007-03-08 |
| JP2007505163A5 JP2007505163A5 (https=) | 2007-08-09 |
Family
ID=33490633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533504A Pending JP2007505163A (ja) | 2003-05-27 | 2004-05-27 | Ｓａｒｓ感染の画像解析可能な動物モデル |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050039220A1 (https=) |
| EP (1) | EP1628996A4 (https=) |
| JP (1) | JP2007505163A (https=) |
| CN (1) | CN1829732A (https=) |
| AU (1) | AU2004243886A1 (https=) |
| CA (1) | CA2527296A1 (https=) |
| WO (1) | WO2004106497A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023523828A (ja) * | 2020-04-30 | 2023-06-07 | ヤン シェン ターン カンパニー リミテッド | コロナウイルス感染の遮断薬をスクリーニングする検出試薬及び検出方法 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102669017B (zh) * | 2011-12-19 | 2015-02-25 | 河南科技大学 | 一种体内细菌生物被膜感染动物模型的构建方法 |
| WO2021147025A1 (en) * | 2020-01-22 | 2021-07-29 | The University Of Hong Kong-Shenzhen Hospital | Anti 2019-ncov vaccine |
| CN114360646A (zh) * | 2020-04-03 | 2022-04-15 | 郑鑫 | 类似sars冠状病毒溯源和评估致病力的方法及装置 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001071009A2 (en) * | 2000-03-17 | 2001-09-27 | Anticancer, Inc. | Whole-body optical imaging of gene expression and uses thereof |
| WO2002092827A2 (en) * | 2001-05-17 | 2002-11-21 | Universiteit Utrecht | Corona-virus-like particles comprising functionally deleted genomes |
| WO2003006069A1 (en) * | 2001-07-09 | 2003-01-23 | Anticancer, Inc. | Imaging infection using fluorescent protein as a marker |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251384B1 (en) * | 1997-04-28 | 2001-06-26 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
| US6232523B1 (en) * | 1997-04-28 | 2001-05-15 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
| AU749338B2 (en) * | 1997-04-28 | 2002-06-27 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
-
2004
- 2004-05-27 WO PCT/US2004/016976 patent/WO2004106497A2/en not_active Ceased
- 2004-05-27 CN CNA2004800218114A patent/CN1829732A/zh active Pending
- 2004-05-27 US US10/856,529 patent/US20050039220A1/en not_active Abandoned
- 2004-05-27 CA CA002527296A patent/CA2527296A1/en not_active Abandoned
- 2004-05-27 EP EP04753740A patent/EP1628996A4/en not_active Withdrawn
- 2004-05-27 JP JP2006533504A patent/JP2007505163A/ja active Pending
- 2004-05-27 AU AU2004243886A patent/AU2004243886A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001071009A2 (en) * | 2000-03-17 | 2001-09-27 | Anticancer, Inc. | Whole-body optical imaging of gene expression and uses thereof |
| WO2002092827A2 (en) * | 2001-05-17 | 2002-11-21 | Universiteit Utrecht | Corona-virus-like particles comprising functionally deleted genomes |
| WO2003006069A1 (en) * | 2001-07-09 | 2003-01-23 | Anticancer, Inc. | Imaging infection using fluorescent protein as a marker |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023523828A (ja) * | 2020-04-30 | 2023-06-07 | ヤン シェン ターン カンパニー リミテッド | コロナウイルス感染の遮断薬をスクリーニングする検出試薬及び検出方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050039220A1 (en) | 2005-02-17 |
| WO2004106497A3 (en) | 2005-05-12 |
| CA2527296A1 (en) | 2004-12-09 |
| EP1628996A4 (en) | 2008-01-09 |
| EP1628996A2 (en) | 2006-03-01 |
| CN1829732A (zh) | 2006-09-06 |
| WO2004106497A2 (en) | 2004-12-09 |
| AU2004243886A1 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reardon et al. | Rabies virus CVS-N2cΔG strain enhances retrograde synaptic transfer and neuronal viability | |
| Tang et al. | Faithful expression of multiple proteins via 2A-peptide self-processing: a versatile and reliable method for manipulating brain circuits | |
| Kim et al. | High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice | |
| EP3072966B1 (en) | Mitogen-activated protein kinase-dependent recombinant vaccinia virus (md-rvv) and use thereof | |
| EP1281767A2 (en) | Light emitting microorganisms and cells for diagnosis and therapy of tumors | |
| IL263719B2 (en) | Adeno variant-related viruses and methods of use | |
| CN110072559A (zh) | 用于使基因在中间神经元中特异性表达的启动子SynP107 | |
| CN110072557A (zh) | 用于在方向选择性视网膜神经节细胞中特异性表达基因的启动子SynP198 | |
| Soowannayan et al. | Detection and differentiation of yellow head complex viruses using monoclonal antibodies | |
| Oparka et al. | Imaging the green fluorescent protein in plants—viruses carry the torch | |
| JP5863338B2 (ja) | プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット | |
| JPH01501280A (ja) | 欠損組換えレトロウイルス及びかかるレトロウイルスを含む細胞、並びにそれらの産生方法及び使用、特に、野性型レトロウイルスと該野性型レトロウイルスに感染性の細胞系との相互作用の研究または野性型レトロウイルス感染のｉｎ ｖｉｔｒｏ検出のための欠損組換えレトロウイルスの使用 | |
| CN101327226B (zh) | 用于诊断和治疗肿瘤的微生物和细胞 | |
| Ekström et al. | A novel strategy for live detection of viral infection in Drosophila melanogaster | |
| WO2025081670A1 (zh) | 一种荧光报告蛋白 | |
| JP2007505163A (ja) | Ｓａｒｓ感染の画像解析可能な動物モデル | |
| US8334095B2 (en) | Compositions and methods for monosynaptic transport | |
| JP2021502822A (ja) | ｉｎ ｖｉｔｒｏ及びｉｎ ｖｉｖｏでの遺伝子送達のための非ヒトパピローマウイルス | |
| Steele et al. | Ebola virus glycoprotein demonstrates differential cellular localization in infected cell types of nonhuman primates and guinea pigs | |
| US20040224370A1 (en) | Fluorescence guided cell capture | |
| Teninges et al. | Rhabdovirus sigma, the hereditary CO2 sensitivity agent of Drosophila: nucleotide sequence of a cDNA clone encoding the glycoprotein | |
| Famulari et al. | Murine leukemia virus env-gene expression in preleukemic thymocytes and leukemia cells of AKR strain mice | |
| EP2111235A1 (en) | A method for diagnosing disease using adenovirus harboring trans-splicing ribozyme by molecular imaging | |
| JP2021036810A (ja) | 組換え牛白血病ウイルス及びその利用 | |
| US8217222B2 (en) | Methods for identifying markers for early-stage human cancer, cancer progression and recurrence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070525 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100302 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100527 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100901 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110705 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111213 |